AnaptysBio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-13.23	-145.23	-163.62	-128.72	-57.8
Depreciation & Amortization	0.56	0.61	0.65	0.68	0.62
Stock-Based Compensation	36.07	34.05	33.21	27.36	15.35
Other Adjustments	77.02	41.57	9.29	20.26	3.4
Change in Receivables	6.92	-33.91	-5.43	-0.54	-0.88
Changes in Other Operating Activities	-87.64	-32.41	5.11	7.38	-6.61
Operating Cash Flow	19.7	-135.34	-120.8	-73.59	-45.92
Capital Expenditures	-0.09	-0.36	-0.81	-0.36	-1.37
Sale of Property, Plant & Equipment	-	-	-	-	0.02
Purchases of Investments	-196.41	-380.38	-303.92	-802.5	-118.66
Proceeds from Sale of Investments	424.53	476.13	449.48	408.02	158.85
Investing Cash Flow	228.03	95.4	144.75	-394.85	38.84
Long-Term Debt Issued	-	50	-	35	250
Long-Term Debt Repaid	-76.8	-15.23	-11.73	-2.47	-
Net Long-Term Debt Issued (Repaid)	-76.8	34.77	-11.73	32.53	250
Issuance of Common Stock	14.26	100.84	2.47	11.83	2.55
Repurchase of Common Stock	-70.08	-7.96	-50	-	-
Net Common Stock Issued (Repurchased)	-55.82	92.88	-47.53	11.83	2.55
Other Financing Activities	-	-0.6	-0.04	-0.34	-0.26
Financing Cash Flow	-132.61	127.05	-59.3	44.02	252.3
Net Cash Flow	115.12	87.12	-35.34	-424.42	245.21
Free Cash Flow	19.61	-135.7	-121.61	-73.95	-47.29
FCF Margin	8.36%	-148.66%	-708.79%	-718.88%	-74.85%
Free Cash Flow Per Share	0.68	-4.78	-4.52	-2.63	-1.72
Levered Free Cash Flow	-177.2	-142.63	-170.39	-88.5	184.84
Unlevered Free Cash Flow	-39.87	-147.11	-159.46	-107.43	-64.17

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q